US Supreme Court rejects ‘Pharma Bro’ Martin Shkreli’s bid for fines By Reuters

(Reuters) – The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli’s challenge to a $64.6 million fine imposed by a judge after he raised the price of a life-saving drug by more than 4,000 percent.

The justices rejected Shkreli’s request for a lower court ruling upholding the sentence, which is equal to the profits he and one of his former companies made by raising the price of the drug Daraprim in 2015. Shkreli, then 30 years old, was given this nickname. “Pharma Bro” in the media. His sentence was set for 2022 by US District Judge Denise Cote in Manhattan.